Cell and Gene Therapy: Top 20 Terms You Should Know If You’re Just Starting Out Navigating the intricate world of cell and gene therapy can be daunting, especially if you [….]
The Emily Whitehead Foundation has been at the center of the biotech community this week in Philadelphia, with two impactful events supporting their mission to help families, children and researchers activate the cure for childhood cancer and access new CART-T therapies.
This year’s Bio Innovation Conference is back to a full one-day format. Join Maryland Life Sciences, a division of the Maryland Tech Council, for our annual Bio Innovation Conference from [….]
Join us to mix, mingle & celebrate Philly’s contributions to the industry as we cheers to the region’s continued growth.
Three Philadelphia Events you Don’t Want to Miss in June
Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.
Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.
Just recently, UMBC appointed biotech industry veteran Mark Schenerman as Graduate Program Director in Biotechnology, marking an important milestone for the program as it looks to move into a new phase of innovation and growth. Schenerman is an active UMBC biotech professor, runs his own biotech consulting business, and built an impressive biotech career that included more than two decades at MedImmune, one of the most important biotech companies in the region’s history.
After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.
If you’re a scientist, chances are when you hear the name “Charles River Laboratories” (Charles River) you may initially think of their industry-leading research models which are a staple for research labs globally. But did you also know that Charles River offers a plethora of products and services for translational laboratories and life science companies alike that span across the drug development lifecycle?
